leflunomide has not been established as a first-line treatment for polymyalgia rheumatica (PMR). The primary treatment for PMR is corticosteroids, such as prednisone. Corticosteroids are highly effective in reducing inflammation and alleviating the symptoms of PMR. However, long-term use of corticosteroids like prednisone can lead to significant side effects, such as osteoporosis, weight gain, and increased risk of infections.
The use of leflunomide, which is an immunosuppressive medication commonly used in the treatment of rheumatoid arthritis, has been explored as an alternative treatment for PMR in some cases where corticosteroids are not well-tolerated or when there is a need to taper off the steroid dosage due to side effects. There is limited evidence suggesting that leflunomide might be effective in certain cases of PMR, but it is not yet considered a standard or preferred treatment for this condition.
Treatment decisions should be made on an individual basis, considering factors such as the severity of PMR symptoms, the patient's overall health, and their response to different medications. If you or someone you know has PMR, it's essential to consult a healthcare professional who can provide personalized advice and recommend the most appropriate treatment plan based on the specific circumstances and medical history.
As my information is not up-to-date, I recommend checking with a healthcare professional or referring to more recent medical literature and guidelines for the latest information on the treatment of polymyalgia rheumatica.